Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology

This article was originally published in Scrip

Executive Summary

Emboldened by results from their existing alliance on mRNA drugs for cardiovascular, metabolic and regenerative disease, AstraZeneca PLC and privately held Moderna Therapeutics LLC have decided to extend their focus to include candidates for the treatment of a range of cancers.

You may also be interested in...



Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO

Moderna is in no rush to conduct an IPO, but the secretive biopharma unicorn gave potential investors in a future offering a glimpse of its 12 programs in or nearing the clinic at J.P. Morgan’s annual conference.

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal

Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

SC064181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel